CC: VO: 49:39 AW [Eastern Daylight Time] \* SVR: USPTO-EFXRF-6445 \* DNIS: 2738300 \* CSID: 6266080397 \* DURATION (mm-ss): 0782 \* SVB \* RCVD AT 812912006 11:49:59 AM [Eastern Daylight Time] \* SVR: USPTO-EFXRF-6445 \* DNIS: 2738300 \* CSID: 6266080397 \* DURATION (mm-ss): 0782 \* DNIS: 2738300 \* CSID: 6266080397 \* DURATION (mm-ss): 0782 \* DNIS: 2738300 \* CSID: 6266080397 \* DURATION (mm-ss): 0782 \* DNIS: 2738300 \* CSID: 6266080397 \* DURATION (mm-ss): 0782 \* DNIS: 2738300 \* CSID: 6266080397 \* DURATION (mm-ss): 0782 \* DNIS: 2738300 \* CSID: 6266080397 \* DNIS: 2738300 \* DNIS: 27383

## Amendments on the original claims

## What is claimed is:

1. A phenylaminopyrimidine derivative compound (35 U.S.C. 112) of formula (1)

Formula (I)

Wherein

X is oxygen or sulfur,

Y is a direct bond, oxygen, nitrogen or lower alkyl,

Z is an aliphatic, cycloaliphatic, aryl or a heterocyclyl radical,

R<sub>1</sub> is heterocyclyl radical,

R<sub>2</sub> is hydrogen, halogen, halogenlower alkyl, lower alkyl or lower alkoxyl,

R<sub>3</sub> is hydrogen or lower alkyl,

R<sub>4</sub> is oxy-lower alkylamino, lower alkyl oxy-lower alkylamino, oxyheterocyclyl, lower alkyl oxyheterocyclyl, oxy-lower alkylheterocyclyl, lower alkylamino oxy-lower alkylheterocyclyl, halogenlower alkylamino, halogenlower alkylamino lower alkylamino, lower alkylamino, (35 U.S.C. 102, 35 U.S.C. 103) lower alkylamino lower alkylamino,

aminoheterocyclyl with the proviso that heterocyclyl defined herein is not selected from N-lower alkylpyrrolidinyl or N-lower alky piperidinyl, (35 U.S.C. 102, 35 U.S.C. 103)

lower alkylamino heterocyclyl with the proviso that lower alkyamino defined herein is not para-substituted with  $-CH_2NH$ -when Z is the phenyl ring, (35 U.S.C. 102, 35 U.S.C. 103)

amino lower alkylheterocyclyl or lower alkylamino lower alkylheterocyclyl, or a pharmaceutically acceptable salt thereof.

BYCE 3138 & BCAD VI 813813000 41:48:28 VW [Esstem Daylight Lime] 2AB:10210-ELXB-0/42 DNIS:3538300 . CSID:050000305 DNBVIION (mm-cs):05-35 Application Number: 10/821,382

2. A compound of Formula (I) according to claim 1, wherein

X is oxygen or sulfur,

Y is a direct bond, oxygen, nitrogen or lower alkyl,

Z is an aliphatic, cycloaliphatic, aryl or a heterocyclyl radical,

R<sub>1</sub> is heterocyclyl radical,

R2 is hydrogen, halogen, halogenlower alkyl, lower alkyl or lower alkoxyl,

R<sub>3</sub> is hydrogen or lower alkyl,

R<sub>4</sub> is:

- (a) oxy-lower alkyl unsubstituted, mono or disubstituted amino; oxy-lower alkyl morpholinyl, oxy-lower alkyl pyrrolidinyl, oxy-lower alkyl piperazinyl, oxy-lower alkyl-aminopyridinyl, (35 U.S.C. 112) oxy-pyrrolidinyl, oxy-piperidinyl,
- (b) lower alkyl oxy-lower alkyl unsubstituted, mono or disubstituted amino; lower alkyl oxy-lower alkyl morpholinyl, lower alkyl oxy-lower alkyl pyrrolidinyl, lower alkyl oxy-lower alkyl piperazinyl, lower alkyl oxy-lower alkyl piperazinyl, lower alkyl oxy-lower alkyl aminopyridinyl, (35 U.S.C. 112) lower alkyl oxy-pyrrolidinyl, lower alkyl oxy-piperidinyl,
- (c) mono or difluoro substituted lower alkyl unsubstituted, mono or disubstituted amino; mono or difluoro substituted lower alkyl morpholinyl, mono or difluoro substituted lower alkyl piperidinyl, mono or difluoro substituted lower alkyl piperidinyl, mono or difluoro substituted lower alkyl piperazinyl, mono or difluoro substituted lower alkyl piperazinyl, mono or difluoro substituted lower alkyl aminopyridinyl, (35 U.S.C. 112)
- (d) amino lower alkyl unsubstituted, mono or disubstituted amino; amino lower alkyl morpholinyl, amino lower alkyl pyrrolidinyl, amino lower alkyl piperidinyl, amino lower alkyl piperazinyl, amino lower alkyl aminopyridinyl, (35 U.S.C. 112)

amino pyrrolidinyl, amino piperidinyl with the proviso that pyrrolidinyl or piperidinyl defined herein is not selected from N-lower alkylpyrrolidinyl or N-lower alky piperidinyl, (35 U.S.C. 102, 35 U.S.C. 103)

(e) lower alkylamino lower alkyl unsubstituted, mono or disubstituted amino; lower alkylamino lower alkylami

byce 4/38 \* RCVD AT 8/29/2006 11:49:59 AM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-6/45 \* DNIS:2738300 \* CSID:6266080397 \* DURATION (mm-ss):07-32

lower alkylamino lower alkyl piperidinyl, lower alkylamino lower alkyl piperazinyl, lower alkylamino lower alkyl aminopyridinyl, (35 U.S.C. 112)

lower alkylamino heterocyclyl with the proviso that lower alkyamino defined herein is not para-substituted with -CH<sub>2</sub>NH- when Z is the phenyl ring, (35 U.S.C. 102, 35 U.S.C. 103)

or a pharmaceutically acceptable salt thereof.

3. A compound of Formula (I) according to claim 1, wherein

X is oxygen or sulfur,

Y is a direct bond,

Z is an aliphatic, cycloaliphatic, aryl or a heterocyclyl radical,

R<sub>1</sub> is heterocyclyl radical,

R<sub>2</sub> is hydrogen, halogen, halogenlower alkyl, lower alkyl or lower alkoxyl,

R<sub>3</sub> is hydrogen or lower alkyl,

R<sub>4</sub> is:

- (a) oxy-lower alkyl unsubstituted, mono or disubstituted amino; oxy-lower alkyl morpholinyl, oxy-lower alkyl pyrrolidinyl, oxy-lower alkyl piperazinyl, oxy-lower alkyl-aminopyridinyl, (35 U.S.C. 112) oxy-pyrrolidinyl, oxy-piperidinyl,
- (b) lower alkyl oxy-lower alkyl unsubstituted, mono or disubstituted amino; lower alkyl oxy-lower alkyl morpholinyl, lower alkyl oxy-lower alkyl pyrrolidinyl, lower alkyl oxy-lower alkyl piperazinyl, lower alkyl oxy-lower alkyl piperazinyl, lower alkyl oxy-lower alkyl oxy-pyrrolidinyl, lower alkyl oxy-pyrrolidinyl, lower alkyl oxy-piperidinyl,
- (c) mono or difluoro substituted lower alkyl unsubstituted, mono or disubstituted amino; mono or difluoro substituted lower alkyl morpholinyl, mono or difluoro substituted lower alkyl piperidinyl, mono or difluoro substituted lower alkyl piperidinyl, mono or difluoro substituted lower alkyl piperazinyl, mono or difluoro substituted lower alkyl piperazinyl, mono or difluoro substituted lower alkyl piperazinyl, mono or difluoro substituted lower alkyl aminopyridinyl, (35 U.S.C. 112)
- (d) amino lower alkyl-unsubstituted, mono or disubstituted amino; amino lower alkyl morpholinyl, amino lower alkyl pyrrolidinyl, amino lower alkyl piperidinyl, amino lower alkyl aminopyridinyl, (35 U.S.C. 112)

BAGE 5/128 \* RCVD AT 8/29/2006 1/1:49:59 AM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-6/45 \* DNIS:2738300 \* CSID:6266080397 \* DURATION (mm-ss):07-32

amino pyrrolidinyl, amino piperidinyl with the proviso that pyrrolidinyl or piperidinyl defined herein is not selected from N-lower alkylpyrrolidinyl or N-lower alky piperidinyl, (35 U.S.C. 102, 35 U.S.C. 103)

(e) lower alkylamino lower alkyl unsubstituted, mono or disubstituted amino; lower alkylamino lower alkyl morpholinyl, lower alkylamino lower alkyl piperidinyl, lower alkylamino lower alkyl piperazinyl, lower alkylamino lower alkylamino lower alkylamino lower alkylamino lower alkylaminopyridinyl, (35 U.S.C. 112)

lower alkylamino heterocyclyl with the proviso that lower alkylamino defined herein is not para-substituted with  $-CH_2NH$ — when Z is the phenyl ring, (35 U.S.C. 102, 35 U.S.C. 103)

or a pharmaceutically acceptable salt thereof.

4. A compound of Formula (I) according to claim 1, wherein

X is oxygen or sulfur,

Y is a direct bond,

Z is aryl,

R<sub>1</sub> is heterocyclyl radical,

R<sub>2</sub> is hydrogen, halogen, halogenlower alkyl, lower alkyl or lower alkoxyl,

R<sub>3</sub> is hydrogen or lower alkyl,

R4 is:

- (a) oxy-lower alkyl unsubstituted, mono or disubstituted amino; oxy-lower alkyl morpholinyl, oxy-lower alkyl pyrrolidinyl, oxy-lower alkyl piperazinyl, oxy-lower alkyl aminopyridinyl, (35 U.S.C. 112) oxy-pyrrolidinyl, oxy-piperidinyl,
- (b) lower alkyl oxy-lower alkyl unsubstituted, mono or disubstituted amino; lower alkyl oxy-lower alkyl morpholinyl, lower alkyl oxy-lower alkyl pyrrolidinyl, lower alkyl oxy-lower alkyl piperazinyl, lower alkyl oxy-lower alkyl piperazinyl, lower alkyl oxy-lower alkyl aminopyridinyl, (35 U.S.C. 112) lower alkyl oxy-pyrrolidinyl, lower alkyl oxy-piperidinyl,
- (c) mono or difluoro substituted lower alkyl unsubstituted, mono or disubstituted amino; mono or difluoro substituted lower alkyl morpholinyl, mono or difluoro substituted lower alkyl pyrrolidinyl, mono or difluoro substituted lower alkyl piperidinyl,

BYCE 9178 & BCAD VI 817817009 11:48:28 VW [Eastern Daylight Time] \* SVR:USPTO-EFXRF-6145 \* DNIS:2738300 \* CSID:6266080397 \* DURATION (mm-ss):07-32 Abblication Number: 10/821,382

mono or difluoro substituted lower alkyl piperazinyl, mono or difluoro substituted lower alkyl aminopyridinyl, (35 U.S.C. 112)

(d) amino lower alkyl unsubstituted, mono or disubstituted amino; amino lower alkyl morpholinyl, amino lower alkyl pyrrolidinyl, amino lower alkyl piperidinyl, amino lower alkyl piperazinyl, amino lower alkyl aminopyridinyl, (35 U.S.C. 112)

amino pyrrolidinyl, amino piperidinyl with the proviso that pyrrolidinyl or piperidinyl defined herein is not selected from N-lower alkylpyrrolidinyl or N-lower alky piperidinyl, (35 U.S.C. 102, 35 U.S.C. 103)

(e) lower alkylamino lower alkyl unsubstituted, mono or disubstituted amino; lower alkylamino lower alkyl morpholinyl, lower alkylamino lower alkyl piperidinyl, lower alkylamino lower alkyl piperazinyl, lower alkylamino lower alkyl aminopyridinyl, (35 U.S.C. 112)

lower alkylamino heterocyclyl with the proviso that lower alkyamino defined herein is not para-substituted with  $-CH_3NH$ - when Z is the phenyl ring, (35 U.S.C. 102, 35 U.S.C. 103)

or a pharmaceutically acceptable salt thereof.

5. A compound of Formula (I) according to claim 1, wherein

X is oxygen or sulfur,

Y is a direct bond.

Z is aryl,

R<sub>1</sub> is heterocyclyl radical,

R<sub>2</sub> is halogenlower alkyl or lower alkyl.

R<sub>3</sub> is hydrogen or lower alkyl,

R4 is:

- (a) oxy-lower alkyl unsubstituted, mono or disubstituted amino; oxy-lower alkyl morpholinyl, oxy-lower alkyl piperidinyl, oxy-lower alkyl piperazinyl, oxy-lower alkyl aminopyridinyl, (35 U.S.C. 112) oxy-pyrrolidinyl, oxy-piperidinyl,
- (b) lower alkyl oxy-lower alkyl unsubstituted, mono or disubstituted amino; lower alkyl oxy-lower alkyl morpholinyl, lower alkyl oxy-lower alkyl piperidinyl, lower alkyl oxy-lower alkyl piperazinyl, lower alkyl oxy-lower alkyl oxy-lower alkyl piperazinyl, lower alkyl oxy-lower alkyl oxy-lower alkyl piperazinyl, lower alkyl oxy-lower alkyl piperazinyl, lower alkyl oxy-lower alkyl oxy-lower alkyl piperazinyl, lower alkyl oxy-lower alk

DAGE 7128 \* RCVD AT 8/29/2006 11:49:59 AM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-6/45 \* DNIS:2738300 \* CSID:6266080397 \* DURATION (mm-ss):07-32

PAGE 7128 \* RCVD AT 8/29/2006 11:49:59 AM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-6/45 \* DNIS:2738300 \* CSID:6266080397 \* DURATION (mm-ss):07-32

lower alkyl aminopyridinyl, (35 U.S.C. 112) lower alkyl oxy-pyrrolidinyl, lower alkyl oxy-piperidinyl,

- (c) mono or difluoro substituted lower alkyl unsubstituted, mono or disubstituted amino; mono or difluoro substituted lower alkyl morpholinyl, mono or difluoro substituted lower alkyl piperidinyl, mono or difluoro substituted lower alkyl piperidinyl, mono or difluoro substituted lower alkyl piperazinyl, mono or difluoro substituted lower alkyl piperazinyl, mono-or difluoro-substituted lower alkyl aminopyridinyl, (35 U.S.C. 112)
- (d) amino lower alkyl unsubstituted, mono or disubstituted amino; amino lower alkyl morpholinyl, amino lower alkyl pyrrolidinyl, amino lower alkyl piperidinyl, amino lower alkyl piperazinyl, amino lower alkyl aminopyridinyl, (35 U.S.C. 112)

amino pyrrolidinyl, amino piperidinyl with the proviso that pyrrolidinyl or piperidinyl defined herein is not selected from N-lower alkylpyrrolidinyl or N-lower alky piperidinyl, (35 U.S.C. 102, 35 U.S.C. 103)

(e) lower alkylamino lower alkyl unsubstituted, mono or disubstituted amino; lower alkylamino lower alkyl morpholinyl, lower alkylamino lower alkyl piperidinyl, lower alkylamino lower alkyl piperazinyl, lower alkylamino lower alkylaminopyridinyl, (35 U.S.C. 112)

lower alkylamino heterocyclyl with the proviso that lower alkyamino defined herein is not para-substituted with  $-CH_2NH$ — when Z is the phenyl ring, (35 U.S.C. 102, 35 U.S.C. 103)

or a pharmaceutically acceptable salt thereof.

6. A compound of Formula (I) according to claim 1, wherein

X is oxygen or sulfur,

Y is a direct bond,

Z is aryl,

R<sub>1</sub> is heterocyclyl radical,

R<sub>2</sub> is lower alkyl,

R<sub>3</sub> is hydrogen,

R4 is:

(a) oxy-lower alkyl unsubstituted, mono or disubstituted amino; oxy-lower alkyl morpholinyl, oxy-lower alkyl pyrrolidinyl, oxy-lower alkyl piperidinyl, oxy-lower alkyl

BYCE 8138 . BCAD BT 815815009 11:48:28 AW [Eastern Daylight Time] . SVR:USPTO-EFXRF-6145 . DNIS:2738300 . CSID:6266080397 . DURATION (mm-ss):07-32 and control of the contr

piperazinyl, <del>oxy-lower-alkyl-aminopyridinyl,</del> (35 U.S.C. 112) oxy-pyrrolidinyl, oxy-piperidinyl,

- (b) lower alkyl oxy-lower alkyl unsubstituted, mono or disubstituted amino; lower alkyl oxy-lower alkyl morpholinyl, lower alkyl oxy-lower alkyl pyrrolidinyl, lower alkyl oxy-lower alkyl piperazinyl, lower alkyl oxy-lower alkyl piperazinyl, lower alkyl oxy-lower alkyl oxy-pyrrolidinyl, lower alkyl oxy-pyrrolidinyl, lower alkyl oxy-piperidinyl,
- (c) mono or difluoro substituted lower alkyl unsubstituted, mono or disubstituted amino; mono or difluoro substituted lower alkyl morpholinyl, mono or difluoro substituted lower alkyl pyrrolidinyl, mono or difluoro substituted lower alkyl piperidinyl, mono or difluoro substituted lower alkyl piperazinyl, mono or difluoro substituted lower alkyl piperazinyl, mono or difluoro substituted lower alkyl aminopyridinyl, (35 U.S.C. 112)
- (d) amino-lower alkyl unsubstituted, mono-or-disubstituted amino; amino lower alkyl morpholinyl, amino lower alkyl pyrrolidinyl, amino lower alkyl piperidinyl, amino lower alkyl piperazinyl, amino lower alkyl aminopyridinyl, (35 U.S.C. 112)

amino pyrrolidinyl, amino piperidinyl with the proviso that pyrrolidinyl or piperidinyl defined herein is not selected from N-lower alkylpyrrolidinyl or N-lower alky piperidinyl, (35 U.S.C. 102, 35 U.S.C. 103)

(e) lower alkylamino lower alkyl unsubstituted, mono or disubstituted amino; lower alkylamino lower alkyl morpholinyl, lower alkylamino lower alkyl piperidinyl, lower alkylamino lower alkyl piperazinyl, lower alkylamino lower alkylamino lower alkylamino lower alkylamino lower alkylamino lower alkylamino lower alkylaminopyridinyl, (35 U.S.C. 112)

lower alkylamino heterocyclyl with the proviso that lower alkyamino defined herein is not para-substituted with  $-CH_2NH$ - when Z is the phenyl ring, (35 U.S.C. 102, 35 U.S.C. 103)

or a pharmaceutically acceptable salt thereof.

7. A compound of Formula (I) according to claim 1, wherein

X is oxygen,

Y is a direct bond,

Z is phenyl.

 $R_1$  is: 3-pyridyl or 4-pyridyl

## DAGE 9128 \* RCVD AT 812912006 11:49:59 AM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-6145 \* DNIS:2738300 \* CSID:62566080397 \* DURATION (mm-ss):07:32

R2 is: methyl, F, Cl or hydrogen,

R<sub>3</sub> is hydrogen,

R<sub>4</sub> is:

DAGE 10/28 \* RCVD AT 8/29/2006 11:49:59 AM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-6/45 \* DNIS:2738300 \* CSID:6266080397 \* DURATION (mm-ss):07-32

Washingth Time] \* SVR:USPTO-EFXRF-6/45 \* DNIS:2738300 \* CSID:6266080397 \* DURATION (mm-ss):07-32

## Application Number: 10/821,382

6266080397

R<sub>4</sub> is (cont'd): (35 U.S.C. 102, 35 U.S.C. 103) Application Number: 10/821,382

6266080397

R is hydrogen, lower alkyl, aliphatic, or cycloaliphatic or heterocyclyl radicals, (35 U.S.C. 112)

or a pharmaceutically acceptable salt thereof.

8. A compound of Formula (I) according to claim 1 is selected from:

[4-(2-aminoethoxy)phenyl]-N-{4-methyl-3-[(4-(3-pyridyl)-pyrimidin-2-

yl)amino]phenyl}carboxamide

N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin 2-yl)amino]phenyl} {4-[(1-methylpyrrolidin-3-

yl)amino]phenyl}carboxamide(35 U.S.C. 102, 35 U.S.C. 103)

[4-(fluoropiperazinylmethyl)phenyl]-N-{4-methyl-3-[(4-(3-pyridyl)-pyrimidin-2-

yl)amino]phenyl}carboxamide

N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}-{4-[(1-methylpyrrolidin-2-yl)amino]phenyl}-{4-[(1-met

yl)methoxy]phenyl}carboxamide

N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}[4-(pyrrolidin-3-

ylamino)phenyl]carboxamide

[4-(aminofluoromethyl)phcnyl]-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-

yl)aminolphenyl}carboxamide

N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}[4-(methylpyrrolidin-3-

ylamino)phenyl]carboxamide

{4-[fluoro(4-methylpiperazinyl)methyl]phenyl}-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-

2-yl)amino]phenyl}carboxamide

[4-(aminodifluoromethyl)phenyl]-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-

yl)aminolphenyl}carboxamide

[4 [methyl(1 methylpyrrolidin 3 yl)amino]phenyl} N {4 methyl 3 - [(4 (3-

pyridyl)pyrimidin 2 yl)amino]phenyl) carboxamide (35 U.S.C. 102, 35 U.S.C. 103)

(4-{fluoro[(1-methylpyrrolidin-3-yl)amino]methyl}phenyl)-N-{4-methyl-3-[(4-(3-

pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

{4-[fluoro(methylpyrrolidin-3-ylamino)methyl]phenyl}-N-{4-methyl-3-[(4-(3-

pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

[4-({[2-(dimethylamino)ethyl]amino}fluoromethyl)phenyl]-N-{4-methyl-3-[(4-(3-

pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

Application Number: 10/821,382

```
[4-(difluoropiperazinylmethyl)phenyl]-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-
yl)amino]phenyl}carboxamide
{4-[difluoro(4-methylpiperazinyl)methyl]phenyl}-N-{4-methyl-3-[(4-(3-
pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
[4-({[2-(dimethylamino)ethyl]amino}difluoromethyl)phenyl]-N-{4-methyl-3-[(4-(3-
pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
(4-{fluoro[methyl(1-methylpyrrolidin-3-yl)amino]methyl}-phenyl)-N-{4-methyl-3-[(4-
(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
{4-[fluoro(pyrrolidin-3-ylamino)methyl]phenyl}-N-{4-methyl-3-[(4-(3-
pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
{4-[(4-ethylpiperazinyl)difluoromethyl]phenyl}-N-{4-mcthyl-3-[(4-(3-pyridyl)pyrimidin-
2-yl)amino]phenyl}carboxamide
{4-[(4-ethylpiperazinyl)fluoromethyl]phenyl}-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-
2-yl)amino]phenyl}carboxamide
(4-{difluoro[methyl(1-methylpyrrolidin-3-yl)amino]methyl}-phenyl)-N-{4-methyl-3-[(4-
(3-pyridyl)pyrimidin-2-yl)amino|phenyl}carboxamide
{4-[difluoro(methylpyrrolidin-3-ylamino)methyl]phenyl}-N-{4-methyl-3-[(4-(3-
pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
[4-({[2-(dimethylamino)ethyl]amino}fluoromethyl)phenyl]-N-{4-methyl-3-[(4-(3-
pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
{4-[difluoro(pyrrolidin-3-ylamino)methyl]phenyl}-N-{4-methyl-3-[(4-(3-
pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
(4-{[methyl(1-methylpyrrolidin-3-yl)amino]methyl}phenyl)-N-{4-methyl-3-[(4-(3-
pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
{4-(methylpyrrolidin-3-ylamino)methylphenyl}-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-
2-yl)amino]phenyl}carboxamide
(4-{[(1 methylpyrrolidin-3-yl)amino}methyl}phenyl)-N-(4 methyl-3-[(1 (3-
pyridyl)pyrimidin 2 yl)amino]phenyl}carboxamide(35 U.S.C. 102, 35 U.S.C. 103)
[4-(pyrrolidin-3-ylamino)methylphenyl] N [4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-
yl)amine]phenyl)carboxamide(35 U.S.C. 102, 35 U.S.C. 103)
or a pharmaceutically acceptable salt thereof.
```

08/29/2005 09:00 6266080397 ADVENCHEN LABS PAGE 14

Application Number: 10/821,382

- 9. A pharmaceutical acceptable salt according to any one of claims 1 to 8 is methanesulfonic acid salt.
- 10. A pharmaceutical composition eentaining which comprises as an active ingredient a compound of formula (I) according to as defined in any one of claims 1 to 9 8 or a pharmaceutical acceptable salt thereof of the compound, or a hydrate or solvate thereof, of the compound and together with a pharmaceutical acceptable carrier.

  [37 CFR 1.75(c), MPEP § 608.01(n)]
- 11. A compound of formula (1) according to any one of claims 1 to 9, or a pharmaceutical acceptable salt thereof, or a hydrate or solvate thereof, for use in a method for the treatment of human or animal cancer. [37 CFR 1.75(c), MPEP § 608.01(n)]